GRIN Therapeutics Announces First Patient Dosed in Phase 1B Clinical Trial with Radiprodil for Treatment of GRIN-related Disorders
Milestone represents initiation of first-ever clinical trial using NR2B-negative allosteric modulator to treat GRIN-related disorders March 23, 2023 07:00 AM Eastern Daylight Time NEW YORK--(BUSINESS WIRE)--GRIN Therapeutics Inc., a leader in development of
Registrati on line alla conferenza GRI 2023
We are delighted to announce that virtual registration for #GRIcon2023 is now OPEN!The virtual conference is a Pay What You Can event. Our suggested ticket price is $79 per person / household, but
Studio GRIN-FOUNDATION
https://it.m.wikipedia.org/wiki/CRISPR